PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas.
CIBERSORT
RPLHR
TMB
glioma
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
10
2020
accepted:
25
05
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
9
7
2022
Statut:
epublish
Résumé
Tumor mutation burden (TMB) is a useful biomarker for predicting the prognosis and efficacy of immune checkpoint inhibitor (ICIs). In this study, we aimed to explore the prognostic value of TMB and TMB-related PRLHR immune genes as prognostic markers in patients with gliomas. We downloaded MAF files, RNA-seq data, and clinical information from the Cancer Genome Atlas (TCGA) database. The TMB of glioma was calculated and its correlation with clinical features and prognosis was analyzed. We found that TMB was statistically correlated with the grade and age of patients with gliomas. Kaplan-Meier curve analysis showed that low TMB was associated with better clinical outcome in patients with gliomas. Additionally, a predictive model based on five HUB genes (
Identifiants
pubmed: 35800054
doi: 10.3389/fonc.2022.620190
pmc: PMC9253814
doi:
Types de publication
Journal Article
Langues
eng
Pagination
620190Informations de copyright
Copyright © 2022 Liu, Xiang, Peng and Shen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Invest. 2019;37(1):1-7
pubmed: 30632816
Front Immunol. 2018 Dec 21;9:2924
pubmed: 30619286
Cell. 2019 Nov 14;179(5):1191-1206.e21
pubmed: 31730857
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Int J Cancer. 2019 May 1;144(9):2303-2312
pubmed: 30446996
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Cancer Lett. 2016 Jun 1;375(2):263-273
pubmed: 26966000
Cancers (Basel). 2020 Sep 21;12(9):
pubmed: 32967190
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
BMC Immunol. 2019 Jan 11;20(1):4
pubmed: 30634925
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207126
Breast Cancer Res. 2015 Aug 05;17:101
pubmed: 26243145
Immunotherapy. 2018 Feb 1;10(4):317-339
pubmed: 29421984
BMC Gastroenterol. 2015 Aug 25;15:107
pubmed: 26302849
J Neurooncol. 2017 Dec;135(3):571-579
pubmed: 28861666
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Front Oncol. 2020 Aug 20;10:1409
pubmed: 32974146
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2187-92
pubmed: 23284171
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Neurotherapeutics. 2017 Apr;14(2):284-297
pubmed: 28281173
Immunol Res. 2014 May;58(2-3):234-9
pubmed: 24791905
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cell Physiol Biochem. 2018;47(1):428-439
pubmed: 29794476
Cancers (Basel). 2021 Jun 22;13(13):
pubmed: 34206554
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Nat Rev Neurol. 2015 Sep;11(9):504-14
pubmed: 26260659